Pfizer Company Profile
✉ Email this page to a colleague
What is the competitive landscape for PFIZER, and when can generic versions of PFIZER drugs launch?
PFIZER has one hundred and ninety-four approved drugs.
There are forty-eight US patents protecting PFIZER drugs. There is one tentative approval on PFIZER drugs.
There are one thousand and twenty-four patent family members on PFIZER drugs in seventy countries and two hundred and sixty supplementary protection certificates in nineteen countries.
Summary for Pfizer
| International Patents: | 1024 |
| US Patents: | 48 |
| Tradenames: | 159 |
| Ingredients: | 130 |
| NDAs: | 194 |
| Drug Master File Entries: | 3 |
| Patent Litigation for Pfizer: | See patent lawsuits for Pfizer |
| PTAB Cases with Pfizer as petitioner: | See PTAB cases with Pfizer as petitioner |
Drugs and US Patents for Pfizer
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pfizer | TALZENNA | talazoparib tosylate | CAPSULE;ORAL | 211651-002 | Oct 16, 2018 | RX | Yes | Yes | 10,189,837 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
| Pfizer | STERANE | prednisolone | TABLET;ORAL | 009996-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Pfizer | MINIZIDE | polythiazide; prazosin hydrochloride | CAPSULE;ORAL | 017986-003 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Pfizer | PROSTIN E2 | dinoprostone | SUPPOSITORY;VAGINAL | 017810-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Pfizer Inc | ELLENCE | epirubicin hydrochloride | INJECTABLE;INJECTION | 050778-002 | Sep 15, 1999 | AP | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Pfizer | DEPO-MEDROL | methylprednisolone acetate | INJECTABLE;INJECTION | 011757-001 | Approved Prior to Jan 1, 1982 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Pfizer
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Pfizer | MICRONASE | glyburide | TABLET;ORAL | 017498-002 | May 1, 1984 | 3,507,961 | ⤷ Try a Trial |
| Pfizer | FELDENE | piroxicam | CAPSULE;ORAL | 018147-003 | Apr 6, 1982 | 4,100,347 | ⤷ Try a Trial |
| Pfizer | TROVAN | trovafloxacin mesylate | TABLET;ORAL | 020759-001 | Dec 18, 1997 | 5,164,402 | ⤷ Try a Trial |
| Pfizer | COVERA-HS | verapamil hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 020552-002 | Feb 26, 1996 | 5,082,668 | ⤷ Try a Trial |
| Pfizer | ZITHROMAX | azithromycin | TABLET;ORAL | 050730-001 | Jun 12, 1996 | 6,268,489 | ⤷ Try a Trial |
| Pfizer | GLYNASE | glyburide | TABLET;ORAL | 020051-001 | Mar 4, 1992 | 3,426,067 | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for PFIZER drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 1 g | ➤ Subscribe | 2005-08-23 |
| ➤ Subscribe | Delayed-release Tablets | 75 mg/0.2 mg | ➤ Subscribe | 2008-11-28 |
| ➤ Subscribe | Extended-release Tablets | 4 mg and 8 mg | ➤ Subscribe | 2012-10-31 |
| ➤ Subscribe | Injection | 20 mg/mL, 2 mL and 5 mL vials | ➤ Subscribe | 2004-07-26 |
| ➤ Subscribe | Capsules | 5 mg and 10 mg | ➤ Subscribe | 2005-06-21 |
| ➤ Subscribe | For Injection | 500 mg/vial | ➤ Subscribe | 2011-06-17 |
| ➤ Subscribe | Oral Suspension | 100 mg/5 mL | ➤ Subscribe | 2009-08-03 |
| ➤ Subscribe | Injection | 2 mg/mL, 100 mL bag | ➤ Subscribe | 2009-12-29 |
| ➤ Subscribe | Tablets | 5 mg | ➤ Subscribe | 2016-11-07 |
| ➤ Subscribe | Delayed-release Tablets | 50 mg/0.2 mg | ➤ Subscribe | 2009-06-29 |
| ➤ Subscribe | Extended-release Tablets | 11 mg | ➤ Subscribe | 2016-11-07 |
| ➤ Subscribe | Capsules | 20 mg, 40 mg, 60 mg and 80 mg | ➤ Subscribe | 2005-02-07 |
| ➤ Subscribe | Capsules | 75 mg, 100 mg and 125 mg | ➤ Subscribe | 2019-02-04 |
| ➤ Subscribe | Capsules | 0.125 mg, 0.25 mg, and 0.5 mg | ➤ Subscribe | 2014-05-01 |
| ➤ Subscribe | Tablets | 600 mg | ➤ Subscribe | 2005-12-21 |
| ➤ Subscribe | Injection | 2 mg/mL, 300 mL bag | ➤ Subscribe | 2009-09-01 |
International Patents for Pfizer Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| South Korea | 20200117058 | ⤷ Try a Trial |
| Japan | 2011529049 | ⤷ Try a Trial |
| Russian Federation | 2013123036 | ⤷ Try a Trial |
| Spain | 2865134 | ⤷ Try a Trial |
| South Korea | 20080095915 | ⤷ Try a Trial |
| Australia | 2006210572 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Pfizer Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1304992 | 122013000081 | Germany | ⤷ Try a Trial | PRODUCT NAME: CLINDAMYCIN (ALS CLINDAMYCIN-PHOSPHAT) UND TRETINOIN; NAT. REGISTRATION NO/DATE: 85210.00.00 20130611; FIRST REGISTRATION: IRLAND PA1332/043/001 20130322 |
| 1214076 | C01214076/01 | Switzerland | ⤷ Try a Trial | PRODUCT NAME: DROSPIRENONE + ETHINYLESTRADIOL; REGISTRATION NUMBER/DATE: SWISSMEDIC 57946 13.06.2008 |
| 2603514 | 19C1021 | France | ⤷ Try a Trial | PRODUCT NAME: COMBINAISON DE VABORBACTAME, ET/OU D'UN SEL ET/OU D'UN HYDRATE DE CELUI-CI, ET DE MEROPENEME, ET/OU D'UN SEL ET/OU D'UN HYDRATE DE CELUI-CI, EN PARTICULIER DE MEROPENEME TRIHYDRATE; REGISTRATION NO/DATE: EU/1/18/1334 20181122 |
| 1746976 | LUC00026 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: IRINOTECAN SUCROSOFATE SALT, SUCH AS IRINOTECAN SUCROSOFATE SALT IN A PEGYLATED LIPOSOME, SUCH AS A LIPOSOME COMPRISING 1,2-DISTEAROYL-SN-PHOSPHATIDYLCHOLINE, CHOLESTEROL AND N-(OMEGA-METHOXY-POLY(ETHYLENE GLYCOL) (MOLECULAR WEIGHT 2000)-OXYCARBONYL)-1,2-DISTEAROYLPHOSPHATIDYL ETHANOLAMINE, E.G. IN THE MOLAR RATIO 3:2:0.015; AUTHORISATION NUMBER AND DATE: EU/1/16/1130 20161018 |
| 1746999 | PA2019016,C1746999 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: DAKOMITINIBO MONOHIDRATAS; REGISTRATION NO/DATE: EU/1/19/1354 20190402 |
| 0454511 | 99C0009 | Belgium | ⤷ Try a Trial | PRODUCT NAME: IRBESARTAN / HYDROCHLOROTHIAZIDE; REGISTRATION NO/DATE: EU/1/98/086/001 19981015 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
